





# Parkinson's Disease drug sales to nearly double by 2025

## Datamonitor Healthcare Survey Results




## Parkinson's Disease Predicted Sales



Datamonitor Healthcare estimates that Parkinson's disease sales will grow substantially in the US, Japan, and five major EU markets, expanding from \$3.2bn in 2016 to \$6.0bn in 2025. Growth will be driven by the aging of the susceptible elderly population, US drug price inflation, and uptake of new late-stage treatment options.

## Current treatment/top brands for Parkinson's with future leaders in market



## Key Pipeline Products in Development for Parkinson's Disease

Drug	Lead Company	Target	Drug Type	Phase
Nurelin*	Adamas Pharmaceuticals	NMDA glutamate receptor; dopamine; norepinephrine	Small molecule	Preregistration (US)
APL-130277	Sunovion	Alpha adrenergic receptor; dopamine receptor	Small molecule	Phase III
CVT-301	Acorda Therapeutics	Dopamine receptor	Small molecule	Phase III
ND0612L	NeuroDerm	AADC; dopamine receptor	Small molecule	Phase III
tozadenant	Acorda Therapeutics	Adenosine A2a receptor	Small molecule	Phase III

Source: Biomedtracker  
\*Under development for the indication of "levodopa-induced dyskinesia."

